Maxim Group
http://www.maximgrp.com/Maxim Group is a financial services firm that provides investment banking, asset management, research, and sales & trading to a diverse range of corporate clients, institutional investors and high net worth individuals.
The firm’s research division uses fundamental research and a “bottom up” approach to making investment recommendations. Maxim’s research analysts focus on under-covered, small- to mid-cap names in a variety of sectors including healthcare, technology, retail and others.
-
Galmed Pharma (GLMD) Proposed $75M Public Offering of Ordinary Shares
-
Galmed Pharmaceuticals Ltd. Announces Proposed Public Offering of Ordinary Shares
-
Galmed Pharmaceuticals (GLMD) PT Raised to $30 at Maxim Group
-
Pre-Open Movers 03/15: (SMRT) (RUBI) (CWAY) Higher; (SLDB) (JILL) (SPEX) Lower (more...)
-
UPDATE: Maxim Group Upgrades Galmed Pharmaceuticals (GLMD) to Buy; Favorable Risk/Reward
-
Maxim Group Downgrades Galmed Pharmaceuticals (GLMD) to Hold
-
Galmed Pharmaceuticals (GLMD) PT Raised to $14 at Maxim Group
-
Maxim Group Maintain Buy Rating and $9 PT on Galmed Pharma (GLMD) Following Q4 EPS Miss; 'Lack of N-T Catalysts'
-
Galmed Pharmaceuticals (GLMD) PT Lowered to $9 at Maxim Group
-
Galmed Pharma (GLMD) Surges 38%
-
Streetinsider.com's Hot Lunchtime Reads 4/4: (ESI) (AAPL) (RKUS) (GLMD)
-
Galmed Pharma (GLMD) May Be Worth $24/Share Based on Gilead's Nimbus Deal - Maxim Group
-
Maxim Group Reiterats Bullish Stance on Galmed (GLMD) Following FDA Fast-Track Status; Funded Through Proof-of-Concept Studies in NASH
-
Maxim Group Starts Galmed Pharmaceuticals (GLMD) at Buy, Sees Significant Upside
-
Galmed Pharmaceuticals (GLMD) IPO Opens Higher, Trends Lower

